Literature DB >> 20813184

Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor.

Dennis Merkle1, Ralf Hoffmann.   

Abstract

Prostate carcinomas are among the most frequently diagnosed and death causing cancers affecting males in the developed world. It has become clear that the molecular mechanisms that drive the differentiation of normal prostate cells towards neoplasia involve multiple signal transduction cascades that often overlap and interact. A critical mediator of cellular proliferation and differentiation in various cells (and cancers) is the cAMP-dependent protein kinase, also known as protein kinase A (PKA), and its activating secondary messenger, cAMP. PKA and cAMP have been shown to play critical roles in prostate carcinogenesis and are the subject of this review. In particular we will focus on the cross-talk between PKA/cAMP signaling and that of the androgen receptor. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813184     DOI: 10.1016/j.cellsig.2010.08.017

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  48 in total

Review 1.  Role of gonadal hormones in programming developmental changes in thymopoietic efficiency and sexual diergism in thymopoiesis.

Authors:  Gordana Leposavic; Milica Perisic; Ivan Pilipovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

Authors:  Megan Hall; Bryan Todd; Edwin D Allen; Nga Nguyen; Yoon-Jung Kwon; Vu Nguyen; Jennifer L Hearne; Miguel Martin-Caraballo
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

3.  Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.

Authors:  Xuehong Deng; Bennett D Elzey; Jean M Poulson; Wallace B Morrison; Song-Chu Ko; Noah M Hahn; Timothy L Ratliff; Chang-Deng Hu
Journal:  Am J Cancer Res       Date:  2011-08-18       Impact factor: 6.166

4.  Phosphodiesterase sequence variants may predispose to prostate cancer.

Authors:  Rodrigo B de Alexandre; Anelia D Horvath; Eva Szarek; Allison D Manning; Leticia F Leal; Fabio Kardauke; Jonathan A Epstein; Dirce M Carraro; Fernando A Soares; Tatiyana V Apanasovich; Constantine A Stratakis; Fabio R Faucz
Journal:  Endocr Relat Cancer       Date:  2015-05-15       Impact factor: 5.678

5.  Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling.

Authors:  Li Liu; Zhongying Cao; Jing Chen; Rui Li; Yanhua Cao; Chengliang Zhu; Kailang Wu; Jianguo Wu; Fang Liu; Ying Zhu
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

6.  Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny.

Authors:  Christopher S Willett; Elizabeth M Wilson
Journal:  J Mol Evol       Date:  2018-03-24       Impact factor: 2.395

7.  Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.

Authors:  Wan-yee Tang; Lisa M Morey; Yuk Yin Cheung; Lynn Birch; Gail S Prins; Shuk-mei Ho
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

Review 8.  Modeling prostate cancer in mice: limitations and opportunities.

Authors:  Patrick J Hensley; Natasha Kyprianou
Journal:  J Androl       Date:  2011-06-16

9.  Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells.

Authors:  Jan-Paul Flacke; Hanna Flacke; Avinash Appukuttan; Rein-Jüri Palisaar; Joachim Noldus; Brian D Robinson; H Peter Reusch; Jonathan H Zippin; Yury Ladilov
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

10.  Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.

Authors:  John T Minges; Gail Grossman; Ping Zhang; Tal Kafri; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2015-09-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.